PROJECT OVERVIEW
Delivery timeline: DAP REG Line PV Start Target Q4 2026, PAR CGV6 PV Start Target Q4 2027
Location: Alzey, Germany
Network: Parenteral
The Alzey site will be a next-generation parenteral manufacturing facility focused on injectable medicines and devices for diabetes and obesity treatments like Mounjaro and Zepbound. The site will feature advanced automation, robotics, and sterility assurance systems. Once operational in 2027, it will create around 1,000 permanent jobs and nearly 2,000 construction roles, reinforcing Lilly’s European manufacturing network.
PROJECT TEAM
-
Frank Barry
Senior Advisor - Design Verification Lead
-
Bessena Cabe
Senior Principal Engineer - Project Manager
-
Corinne Crawford
Senior Principal Engineer - Project Manager
-
Mina Michail
Senior Principal Engineer - Project Manager
-
Mike Sharpe
Senior Advisor - Program Manager, Device Assembly Packaging
-
Sebastian Wegener
Senior Director - Project Management